Mirati Therapeutics, Inc.

NASDAQ:MRTX

58.7 (USD) • At close January 22, 2024
Bedrijfsnaam Mirati Therapeutics, Inc.
Symbool MRTX
Munteenheid USD
Prijs 58.7
Beurswaarde 4,117,669,755
Dividendpercentage 0%
52-weken bereik 27.3 - 64.41
Industrie Biotechnology
Sector Healthcare
CEO Dr. Charles M. Baum M.D., Ph.D.
Website https://www.mirati.com

An error occurred while fetching data.

Over Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and

Vergelijkbare Aandelen

Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc.

NTLA

20.98 USD

Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc.

RARE

56.77 USD

Karuna Therapeutics, Inc. logo

Karuna Therapeutics, Inc.

KRTX

329.83 USD

Inari Medical, Inc. logo

Inari Medical, Inc.

NARI

43.47 USD

Patterson Companies, Inc. logo

Patterson Companies, Inc.

PDCO

21.1 USD

Cytokinetics, Incorporated logo

Cytokinetics, Incorporated

CYTK

54.53 USD

Blueprint Medicines Corporation logo

Blueprint Medicines Corporation

BPMC

86 USD

Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc.

VIR

7.72 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)